Zanubrutinib for marginal zone lymphoma in Italy
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study checks how well and how safely zanubrutinib worked for people with marginal zone lymphoma who got the drug through a special access program in Italy. The goal is to learn more about the drug's real-world effects and help future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have marginal zone lymphoma that has come back (relapsed) or has not responded to other treatments (refractory).
- You must have received at least one dose of zanubrutinib through the Named Patient Program between January 2021 and October 2023.
- You must be at least 18 years old when you started taking zanubrutinib.
- You must sign a form agreeing to be in this study and allowing your personal data to be used.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (zanubrutinib, rituximab, and lenalidomide) as the first treatment for marginal zone lymphoma that has spread or is advanced. The goal is to see if this combination is effective and safe for patients who have not had prior treatment.
This trial tests a new targeted drug (orelabrutinib) with or without another drug that targets CD20 (a protein on some immune cells) for people with untreated marginal zone lymphoma. It aims to see if this combination works better than other treatments and may be an option for those who cannot have radiation.
This trial tests a combination of three drugs (orelabrutinib, zebetuzumab, and lenalidomide) for people newly diagnosed with a type of lymphoma called marginal zone lymphoma (MZL). If you qualify, you may receive this treatment to help control the disease.
This trial tests a personalized treatment plan for people with newly diagnosed marginal zone lymphoma (MZL). The treatment is based on a risk score and aims to be more targeted than standard chemotherapy.
This trial tests a combination of targeted drugs for people with a type of lymphoma called marginal zone lymphoma (MZL) that has not been treated before. The drugs attack cancer cells in different ways, and the treatment plan may adjust based on how you respond.
This trial tests a combination of two targeted drugs (zanubrutinib and rituximab) as a first treatment for marginal zone lymphoma. The goal is to see how well this drug pair works for people who have not received any prior cancer therapy.
Hear when a new Marginal Zone Lymphoma(MZL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.